Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elosulfase alfa - BioMarin Pharmaceuticals

Drug Profile

Elosulfase alfa - BioMarin Pharmaceuticals

Alternative Names: BMN-110; GALNS; Recombinant N-acetylgalactosamine-6-sulfatase; rhGALNS; Vimizim

Latest Information Update: 01 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Chondroitinsulfatases; Recombinant proteins
  • Mechanism of Action GALNS protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis IV
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis IV

Most Recent Events

  • 04 Jun 2019 Registered for Mucopolysaccharidosis IV in China (IV)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2016 BioMarin completes a phase III extension trial for Mucopolysaccharidosis IV in USA, Argentina, Brazil, Canada, Denmark, France, Germany, Italy, Japan, South Korea, Netherlands, Norway, Colombia, Portugal, Qatar, Saudi Arabia, Spain, Taiwan and United Kingdom (NCT01415427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top